Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study

Willem J. Lammers, Henk R. Van Buuren, Gideon M. Hirschfield, Harry L A Janssen, Pietro Invernizzi, Andrew L. Mason, Cyriel Y. Ponsioen, Annarosa Floreani, Christophe Corpechot, Marlyn J. Mayo, Pier M. Battezzati, Albert Parés, Frederik Nevens, Andrew K. Burroughs, Kris V. Kowdley, Palak J. Trivedi, Teru Kumagi, Angela Cheung, Ana Lleo, Mohamad H. ImamKirsten Boonstra, Nora Cazzagon, Irene Franceschet, Raoul Poupon, Llorenç Caballeria, Giulia Pieri, Pushpjeet S. Kanwar, Keith D. Lindor, Bettina E. Hansen

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND & AIMS: Noninvasive surrogate end points of long-term outcomes of patients with primary biliary cirrhosis (PBC) are needed to monitor disease progression and evaluate potential treatments. We performed a meta-analysis of individual patient data from cohort studies to evaluate whether patients' levels of alkaline phosphatase and bilirubin correlate with their outcomes and can be used as surrogate end points.

METHODS: We performed a meta-analysis of data from 4845 patients included in 15 North American and European long-term follow-up cohort studies. Levels of alkaline phosphatase and bilirubin were analyzed in different settings and subpopulations at different time points relative to the clinical end point (liver transplantation or death).

RESULTS: Of the 4845 patients, 1118 reached a clinical end point. The median follow-up period was 7.3 years; 77% survived for 10 years after study enrollment. Levels of alkaline phosphatase and bilirubin measured at study enrollment (baseline) and each year for 5 years were strongly associated with clinical outcomes (lower levels were associated with longer transplant-free survival). At 1 year after study enrollment, levels of alkaline phosphatase that were 2.0 times the upper limit of normal (ULN) best predicted patient outcome (C statistic, 0.71) but not significantly better than other thresholds. Of patients with alkaline phosphatase levels ≤2.0 times the ULN, 84% survived for 10 years compared with 62% of those with levels >2.0 times the ULN (P 1.0 times the ULN (P

CONCLUSIONS: Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or death) of patients with PBC and might be used as surrogate end points in therapy trials.

Original languageEnglish
Pages (from-to)1338-1349.e5
JournalGastroenterology
Volume147
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Keywords

  • Autoimmune Liver Disease
  • Biomarker
  • New Therapies
  • Response To Treatment

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study'. Together they form a unique fingerprint.

Cite this